Servier has entered into a definitive agreement with Kaerus Bioscience to acquire KER-0193, a potential first-in-disease treatment for Fragile X syndrome (FXS), the leading...
Enanta Pharmaceuticals, Inc, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, announced that the U.S. Food and Drug Administration...
Astrocyte Pharmaceuticals Inc, a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation...
